Serum proprotein convertase subtilisin/Kexin type 9 and vascular disease in type 2 diabetic patients

Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) levels have been suggested as novel atherosclerotic biomarker. PCSK9 plays important roles in the pathogenesis of atherosclerosis by regulating the degradation of low‐density lipoprotein receptor as well as different inflammatory pathways. Considering the important prognostic role of arterial stiffness in cardiovascular disease (CVD), the aim of the study is to investigate the correlation between PCSK9 levels and arterial stiffness in a cohort of diabetic patients, without previous CV events.

[1]  M. Scuruchi,et al.  PCSK9 Plasma Levels Are Associated with Mechanical Vascular Impairment in Familial Hypercholesterolemia Subjects without a History of Atherosclerotic Cardiovascular Disease: Results of Six-Month Add-On PCSK9 Inhibitor Therapy , 2022, Biomolecules.

[2]  Cheng-gang Zhu,et al.  The predictive utility of circulating PCSK9 levels on diabetes mellitus , 2021, Cardiovascular Diabetology.

[3]  G. Ning,et al.  Association of circulating proprotein convertase subtilisin/kexin type 9 levels and the risk of incident type 2 diabetes in subjects with prediabetes: a population-based cohort study , 2020, Cardiovascular Diabetology.

[4]  Yuan-Lin Guo,et al.  Association of circulating PCSK9 concentration with cardiovascular metabolic markers and outcomes in stable coronary artery disease patients with or without diabetes: a prospective, observational cohort study , 2020, Cardiovascular Diabetology.

[5]  G. Sesti,et al.  Uric Acid and Vascular Damage in Essential Hypertension: Role of Insulin Resistance , 2020, Nutrients.

[6]  P. Stone,et al.  Arterial stiffness and microvascular disease in type 2 diabetes , 2020, European journal of clinical investigation.

[7]  G. Limongelli,et al.  Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long‐term inhibition , 2020, BioFactors.

[8]  G. Hovingh,et al.  PCSK9 as predictor for recurrent cardiovascular disease in familial hypercholesterolemia. , 2019, European journal of preventive cardiology.

[9]  Yuan-Lin Guo,et al.  Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy , 2019, Journal of Translational Medicine.

[10]  Wen Guo,et al.  Association of serum proprotein convertase subtilisin/kexin type 9 with early atherosclerosis in newly diagnosed type 2 diabetes mellitus. , 2019, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[11]  W. Spiering,et al.  Arterial stiffness as a risk factor for cardiovascular events and all‐cause mortality in people with Type 2 diabetes , 2019, Diabetic medicine : a journal of the British Diabetic Association.

[12]  F. Fallarino,et al.  PCSK9 at the crossroad of cholesterol metabolism and immune function during infections , 2017, Journal of cellular physiology.

[13]  Y. Zhang,et al.  Plasma PCSK9 levels are unrelated to arterial stiffness in a community-based, 4.8-year prospective study , 2017, Journal of Human Hypertension.

[14]  M. Banach,et al.  PCSK9 and diabetes: is there a link? , 2017, Drug discovery today.

[15]  P. Magni,et al.  Circulating Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and Arterial Stiffness in a Large Population Sample: Data From the Brisighella Heart Study , 2017, Journal of the American Heart Association.

[16]  A. Hamsten,et al.  Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk Factors , 2016, Circulation.

[17]  Jennifer G. Robinson,et al.  Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. , 2015, The New England journal of medicine.

[18]  Jennifer G. Robinson,et al.  Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. , 2015, The New England journal of medicine.

[19]  Cheng-gang Zhu,et al.  Relation of circulating PCSK9 concentration to fibrinogen in patients with stable coronary artery disease. , 2014, Journal of clinical lipidology.

[20]  Yuan-Lin Guo,et al.  Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease. , 2014, Atherosclerosis.

[21]  Y. Jang,et al.  Association of serum proprotein convertase subtilisin/kexin type 9 with carotid intima media thickness in hypertensive subjects. , 2013, Metabolism: clinical and experimental.

[22]  F. Arturi,et al.  Association between One-Hour Post-Load Plasma Glucose Levels and Vascular Stiffness in Essential Hypertension , 2012, PloS one.

[23]  J. Filipovský,et al.  Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. , 2012, Journal of hypertension.

[24]  E. Ortega,et al.  White blood cell count is associated with carotid and femoral atherosclerosis. , 2012, Atherosclerosis.

[25]  Jonathan C. Cohen,et al.  Genetic and metabolic determinants of plasma PCSK9 levels. , 2009, The Journal of clinical endocrinology and metabolism.

[26]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[27]  G. Sesti,et al.  Metabolic and cardiovascular risk factors in subjects with impaired fasting glucose: the 100 versus 110 mg/dL threshold , 2007, Diabetes/metabolism research and reviews.

[28]  Jonathan C. Cohen,et al.  Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. , 2006, The New England journal of medicine.

[29]  Albert Hofman,et al.  Arterial Stiffness and Risk of Coronary Heart Disease and Stroke: The Rotterdam Study , 2006, Circulation.

[30]  S. Laurent,et al.  Aortic Stiffness Is an Independent Predictor of Fatal Stroke in Essential Hypertension , 2003, Stroke.

[31]  Y. Jang,et al.  Standards of Medical Care in Diabetes-2010 by the American Diabetes Association: Prevention and Management of Cardiovascular Disease , 2010 .